Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Compare Drugs in Cytochrome P450 3A Inhibitors [MoA]

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
Drug Reports Deaths Death Rate Hosp. Life-Threat. Avg Age % Female
PALBOCICLIB 91,024 11,066 12.2% 13,442 870 66.0 yrs 97.7%
AMLODIPINE 64,924 10,161 15.7% 26,787 5,585 62.8 yrs 57.0%
RIBOCICLIB 27,997 4,501 16.1% 6,700 1,220 60.2 yrs 99.0%
OSIMERTINIB 27,750 12,456 44.9% 5,277 757 68.2 yrs 66.0%
AMIODARONE 25,143 3,845 15.3% 13,711 3,889 69.9 yrs 36.9%
MIRABEGRON 20,618 1,338 6.5% 2,589 1,150 69.8 yrs 69.1%
CLARITHROMYCIN 18,945 987 5.2% 6,385 1,129 52.9 yrs 67.0%
RITONAVIR 11,980 1,190 9.9% 2,925 350 43.8 yrs 43.8%
CRIZOTINIB 9,948 3,173 31.9% 2,520 279 58.5 yrs 55.2%
RANOLAZINE 9,522 1,048 11.0% 3,367 105 70.4 yrs 42.0%

Head-to-Head Comparisons

PALBOCICLIB vs AMLODIPINE PALBOCICLIB vs RIBOCICLIB PALBOCICLIB vs OSIMERTINIB PALBOCICLIB vs AMIODARONE AMLODIPINE vs RIBOCICLIB AMLODIPINE vs OSIMERTINIB AMLODIPINE vs AMIODARONE RIBOCICLIB vs OSIMERTINIB RIBOCICLIB vs AMIODARONE OSIMERTINIB vs AMIODARONE
← Back to Cytochrome P450 3A Inhibitors [MoA] Class side effects →